Vertex Pharmaceuticals Incorporated  

(Public, NASDAQ:VRTX)   Watch this stock  
Find more results for VRTX
66.56
-1.74 (-2.55%)
Real-time:   10:57AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 66.17 - 69.49
52 week 58.06 - 89.96
Open 69.49
Vol / Avg. 408,326.00/1.66M
Mkt cap 15.72B
P/E     -
Div/yield     -
EPS -2.04
Shares 236.11M
Beta 0.36
Inst. own 96%
May 7, 2014
Vertex Pharmaceuticals Incorporated Annual Shareholder Meeting - 9:30AM EDT - Add to calendar
May 1, 2014
Q1 2014 Vertex Pharmaceuticals Incorporated Earnings Conference Call - 5:00PM EDT - Add to calendar
May 1, 2014
Q1 2014 Vertex Pharmaceuticals Incorporated Earnings Release - 4:00PM EDT - Add to calendar
Mar 11, 2014
Vertex Pharmaceuticals Incorporated at Barclays Healthcare Conference
Feb 25, 2014
Vertex Pharmaceuticals Incorporated at RBC Capital Markets Healthcare Conference
Feb 24, 2014
Vertex Pharmaceuticals Incorporated at Canaccord Genuity Orphan Drug One-on-One Day
Jan 29, 2014
Q4 2013 Vertex Pharmaceuticals Incorporated Earnings Conference Call - Webcast
Jan 29, 2014
Q4 2013 Vertex Pharmaceuticals Incorporated Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -52.55% -56.73%
Operating margin -78.07% -74.54%
EBITD margin - 6.49%
Return on average assets -30.20% -27.08%
Return on average equity 13.55% -37.78%
Employees 1,800 -
CDP Score - -

Address

50 Northern Avenue
BOSTON, MA 02210
United States - Map
+1-617-9616100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company�s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene. The Company has ongoing clinical programs involving drug candidates intended for the treatment of HCV infection, CF, rheumatoid arthritis, influenza and epilepsy. INCIVEK (telaprevir) achieved initial commercial acceptance following its approval in May 2011. It started marketing KALYDECO in the United States in January 2012.

Officers and directors

Jeffrey M. Leiden M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Ian F. Smith CPA Chief Financial Officer, Executive Vice President
Age: 47
Bio & Compensation  - Reuters
Peter Mueller Ph.D. Executive Vice President - Global Research and Development, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
Stuart A. Arbuckle Executive Vice President, Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Jeffrey A. Chodakewitz M.D. Chief Medical Officer and Senior Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Kenneth L. Horton Executive Vice President, Chief Legal Officer
Age: 46
Bio & Compensation  - Reuters
Paul M. Silva Senior Vice President, Corporate Controller
Age: 47
Bio & Compensation  - Reuters
Megan Pace Senior Vice President - Corporate Communications
Age: 40
Bio & Compensation  - Reuters
Amit K. Sachdev J.D. Senior Vice President - Global Government Strategy, Market Access and Value
Age: 45
Bio & Compensation  - Reuters
Christiana Stamoulis Senior Vice President - Corporate Strategy and Business Development
Age: 43
Bio & Compensation  - Reuters